Quality of life in patients with biliary tract diseases taking UDCAcontaining drug
https://doi.org/10.51793/OS.2024.27.10.010
Abstract
Background. When bile is oversaturated with cholesterol, the dynamic equilibrium between proand antinucleating factors is disturbed, which leads to precipitation of cholesterol crystals and their aggregation into microlites. Excess cholesterol is deposited in the gallbladder wall, where it strengthens the sarcolemmal membrane of smooth muscle cells and disrupts signal transmission. Slow emptying of gallbladder and bile stagnation occur, which increases its precipitation and formation of wall and then cavity biliary sludge. Bile acid preparations, in particular ursodeoxycholic acid, have litholytic action and are basic in treatment of biliary sludge.
Objective. To evaluate and compare the quality of life of patients with biliary sludge taking drugs containing ursodeoxycholic acid. Materials and methods. The dynamics of clinical symptoms (biliary pain, dyspepsia, bitter taste in the mouth) and quality of life of 84 patients with biliary sludge receiving conservative therapy with various ursodeoxycholic acid preparations for three months were evaluated using the SF-36 Quality of Life questionnaire and the Biliary Symptom Severity Questionnaire.
Results. After 3 months in patients with biliary sludge taking different ursodeoxycholic acid preparations, the indices of physical functioning, general condition, vital activity and mental health were studied, as well as the effectiveness of pain syndrome relief were compared by the indices of pain syndrome severity reduction and rapidity of pain relief when taking preparations containing ursodeoxycholic acid. Conclusion. Quality of life of patients with biliary sludge on the background of ursodeoxycholic acid preparations significantly improves. At the same time, relief of biliary symptoms leads to improvement of both physical and mental health indicators.
About the Authors
A. M. Lukmanova
Bashkir State Medical University
Россия
Россия
Alisa M. Lukmanova, Therapy resident
3 Lenin Street, Ufa, 450008
A. R. Isanbaeva
Bashkir State Medical University
Россия
Россия
Albina R. Isanbaeva, Neurology resident
3 Lenin Street, Ufa, 450008
G. M. Sahautdinova
Bashkir State Medical University
Россия
Россия
Gulnar M. Sahautdinova, Dr. of Sci. (Med.), Professor of the Department of Polyclinic Therapy
3 Lenin Street, Ufa, 450008
References
1. Ivashkin V. T., Mayev I. V., Baranskaya E. K., Okhlobystin A. V., Shulpekova Yu. O., Trukhmanov A. S., Sheptulin A. A., Lapina T. L. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. 2016; 26 (3): 64-80. (In Russ.)
2. Tsarkova O. N., Zaprudnov A. M., Kharitonova L. A., et al. Biliary sludge: clinical-diagnostic and therapeutic-preventive aspects. Ros. vestn. perinatologii i pediatrii. 2009; 54 (6). (In Russ.)
3. Shapovalyants S. G., Ardasenov T. B., Freidovich D. A., et al. Problems of modern diagnostics of choledocholithiasis. RZHGK. 2011; 2. (In Russ.)
4. European Association for the Study of the Liver (EASL). EASL Clin-ical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016; 65 (1): 146-181. DOI: 10.1016/j.jhep.2016.03.005.
5. Lammert F., Hirscheld G., Adams D., Liaskou E. Gallstone Disease: Scientific Understanding and Future Treatment. Biliary Disease. Springer, Cham. 2017. P. 229-41. DOI: 10.1007/978-3-319-50168-0_11.
6. Wang J.-Y., Wu S.-D., Abenavoli L., et al. Ursodeoxycholic Acid for the Treatment of Liver Diseases. Liver PathophysiolTher Antioxidants. 2017; p. 767-779. DOI: 10.1016/B978-0-12-804274-8.00055-.
7. Agafonova N. A., Yakovenko E. P., Yakovenko A. V., Ivanov A. N. Biliary sludge: possibilities of conservative therapy. Lechebnoe delo. 2016; 3. (In Russ.)
8. Radchenko V. G., Seliverstov P. V., Sitkin S. I. New aspects of the pharmacologic action of ursodeoxycholic acid. Eksperimentalnaya i klinicheskaya gastroenterologiya. 2014; 8. (In Russ.)
9. Ozel Coskun B. D., Yucesoy M., Gursoy S., et al. Efects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apoli-poprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2015; 27 (2): 142-149. DOI: 10.1097/MEG.0000000000000264.
10. Roma M. G., Toledo F. D., Boaglio A. C., et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond). 2011; 121: 523-544. DOI: 10.1042/CS20110184.
11. Ivashkin V. T., Okhlobystin A. V., Bordin D. S., Osipenko M. F., Selezneva E. Ya., Shulpekova Yu. O. Expert Committee: Abdulkhakov S. R., Alekseeva O. P., Bakulin I. G., Vologzhanina L. G., Grinevich V. B., Bakulina N. V., Bakulina N. V., Kolesova T. A., Korochanskaya N. V., Putintseva I. V., Sarsenbaeva A. S., Yazenok N. S. Resolution of the Expert Council "Diagnosis and treatment of patients with gallbladder sludge". Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2016; 26 (6). (In Russ.)
12. Savelyev V. S., Petukhov V. A., Karalkin A. V., Fomin D. K. Extrahepatic biliary dysfunctions in lipid distress syndrome: etiopathogenesis, diagnosis and principles of treatment. RMZh. Diseases of the digestive organs. 2002; 2 (4). (In Russ.)
13. Ilchenko A. A., Bystrovskaya E. A. Experience of using duspatalin in functional disorders of sphincter of Oddi in patients who underwent cholecystectomy. Еksperimentalnaja i klinicheskaja gastroenterologija. 2002; 4. (In Russ.)
14. Guarino M. P., Cong P., Cicala M., et al. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. 2007; 56.
15. Solá S., Aranha M. M., Steer C. J., Rodrigues C. M. Game and players: mitochondrial apoptosis and the therapeutic potential of ursodeoxycholic acid. Curr. IssuesMol. Biol. 2007; 2 (9).
16. Kotb M. A. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. Int. J. Mol. Sci. 2012; 7 (13).
Review
For citations:
Lukmanova A.M., Isanbaeva A.R., Sahautdinova G.M. Quality of life in patients with biliary tract diseases taking UDCAcontaining drug. Lechaschi Vrach. 2024;(10):66-71. (In Russ.) https://doi.org/10.51793/OS.2024.27.10.010
Views:
117
JATS XML
Email this article 
